Cartesian Therapeutics (RNAC) Shares Outstanding (2015 - 2026)

Cartesian Therapeutics (RNAC) has 11 years of Shares Outstanding (Entity) data on file, last reported at $28.5 million in Q1 2026.

• On a quarterly basis, Shares Outstanding (Entity) rose 10.06% year-over-year to $28.5 million in Q1 2026; TTM through Mar 2026 was $28.5 million, a 10.06% increase from a year earlier, with the FY2025 full-year figure at $26.0 million, up 50.55% from the prior year.
• Shares Outstanding (Entity) for Q1 2026 stood at $28.5 million, up from $26.0 million in the prior quarter.
• Over the last five years, Shares Outstanding (Entity) for RNAC reached as high as $28.5 million in Q1 2026 and fell as low as $4.1 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $14.0 million across 5 years, with a median of $5.5 million in 2024.
• Across the five-year window, Shares Outstanding (Entity) gained 0.47% in 2023 and soared 370.21% in 2025, its largest moves.
• Year by year, Shares Outstanding (Entity) stood at $5.1 million in 2022, then advanced by 5.81% to $5.4 million in 2023, then jumped by 220.12% to $17.3 million in 2024, then soared by 50.55% to $26.0 million in 2025, then gained by 9.74% to $28.5 million in 2026.
• Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $28.5 million in Q1 2026, $26.0 million in Q4 2025, and $26.0 million in Q3 2025.